WO2008047779A1 - Agent thérapeutique ou prophylactique pour la dermatite atopique - Google Patents

Agent thérapeutique ou prophylactique pour la dermatite atopique Download PDF

Info

Publication number
WO2008047779A1
WO2008047779A1 PCT/JP2007/070144 JP2007070144W WO2008047779A1 WO 2008047779 A1 WO2008047779 A1 WO 2008047779A1 JP 2007070144 W JP2007070144 W JP 2007070144W WO 2008047779 A1 WO2008047779 A1 WO 2008047779A1
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
atopic dermatitis
molecular weight
administration
day
Prior art date
Application number
PCT/JP2007/070144
Other languages
English (en)
Japanese (ja)
Inventor
Akira Asari
Original Assignee
Glycoscience Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycoscience Laboratories, Inc. filed Critical Glycoscience Laboratories, Inc.
Priority to JP2008539816A priority Critical patent/JP5457675B2/ja
Publication of WO2008047779A1 publication Critical patent/WO2008047779A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to prevention and prevention of atopic dermatitis comprising low molecular weight hyaluronic acid as an active ingredient.
  • It relates to a pharmaceutical composition for treatment.
  • Atopic dermatitis is an allergic constitution called atopic predisposition, such as allergic asthma, allergic rhinitis, dermatitis, and chronic skin with itching caused by various stimuli. Is a disease.
  • the diagnostic criteria of the Japanese Dermatological Association define skin diseases mainly consisting of eczema with itching and atopic dermatitis that repeat exacerbations and remissions, and many patients have the ability to have atopic predisposition. Not necessary. Therefore, the term “atopic dermatitis” may be used for diagnosis, including contact dermatitis. In general, it exhibits chronic eczema symptoms over a wide area, becomes dry and blows white powder on the surface, and is accompanied by strong itching. Some patients may have red eczema, nodules, etc.
  • Tissue fluid leaches out from the wet phase, causing severe pain. When it becomes chronic, it becomes rough as if it were goosebumps, and the skin gradually thickens or sometimes has a lump-like wart-like rash.
  • Atopic dermatitis develops in early childhood and often remits spontaneously before reaching adulthood.
  • the goal is to alleviate the symptoms by symptomatic treatment with anti-itch drugs such as steroids and antihistamines.
  • anti-itch drugs such as steroids and antihistamines.
  • Treatment that suppresses excessive immunity by administration of external or internal steroids, or protects the dried part with a moisturizer such as petrolatum is the mainstream.
  • steroids that are said to have the highest therapeutic effect! / Are caused by a phenomenon called rebound that rebounds more strongly than the original symptom, and the effect is reduced by long-term continuous use. (Takifiraki 1) may occur.
  • topical steroids have been used for a long time Then, it is known that skin atrophy, induction of skin infection, and telangiectasia appear, and it is difficult to control steroid dosage and administration period according to symptoms. There has been a demand for the development of therapeutic agents with fewer side effects than steroids.
  • Patent Document 1 discloses a therapeutic drug for atopic dermatitis containing ⁇ -polylysine as an active ingredient and hyaluronic acid as a humectant.
  • Patent Document 2 describes that a sheet in which hyaluronic acid and hydrolyzed silk are contained in a silk nonwoven fabric is used for the prevention and treatment of atopic dermatitis.
  • Patent Document 3 discloses an external preparation for skin containing borage seed oil and vegetable ceramide extracted from wheat germ as main components and hyaluronic acid as a functional component.
  • Patent Document 4 describes a skin external preparation containing eicosapentaenoic acid or docosahexaenoic acid and hyaluronic acid as a moisturizing agent.
  • hyaluronic acid is used only as a moisturizing agent and is not contained as an active ingredient in the treatment of atopic dermatitis.
  • Hyaluronic acid is so-called high molecular weight hyaluronic acid (for example, weight average molecular weight of about 900,000) and does not contain low molecular weight hyaluronic acid, particularly hyaluronic acid tetrasaccharide.
  • Patent Document 1 Japanese Unexamined Patent Application Publication No. 2005-035914
  • Patent Document 2 Japanese Patent Laid-Open No. 2003-212715
  • Patent Document 3 Japanese Patent Laid-Open No. 2002-053428
  • Patent Document 4 JP 2000-095683 A
  • An object of the present invention is to provide a therapeutic agent with a high therapeutic effect that can be substituted for a steroid agent in the prevention and / or treatment of atopic dermatitis.
  • the present inventor has found that low molecular weight hyaluronic acid, particularly hyaluronic acid tetrasaccharide, has an effect of suppressing inflammation due to atopic dermatitis, and that administration can reduce symptoms of atopic dermatitis. I found it. [0008] That is, the present invention provides a therapeutic or prophylactic agent for atopic dermatitis comprising low molecular weight hyaluronic acid as an active ingredient.
  • low molecular weight hyaluronic acid is disaccharide (molecular weight about 400), trisaccharide (molecular weight about 400).
  • tetrasaccharide molecular weight about 800
  • pentasaccharide molecular weight about 1000
  • hexasaccharide molecular weight 1200
  • hyaluronic acid power molecular weight of about 800
  • a therapeutic agent having a high therapeutic effect and having no side effects or having no side effects when preventing and / or treating atopic dermatitis.
  • FIG. 1 shows the results of measuring the thickness of the left auricle of an atopic dermatitis model mouse in Example 1.
  • FIG. 2 is a color photograph of an affected area of an atopic dermatitis model mouse in Example 1.
  • FIG. 4 is a color photograph taken of an affected area of a patient in Example 2.
  • Hyaluronic acid is a macromolecular long-chain polysaccharide composed of a disaccharide repeating unit of D-glucuronic acid and N-acetyl-D-darcosamine, while oligosaccharides are also known.
  • the molecular weight hyaluronic acid is a hyaluronic acid disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, or hexasaccharide (molecular weight of about 400 to about 1200), and particularly, hyanolonic acid tetrasaccharide.
  • the low molecular weight hyaluronic acid contained in the drug of the present invention basically, the 1-position of / 3-D-glucuronic acid and the 3-position of ⁇ D- ⁇ -acetyl-darcosamine 1 were combined.
  • the derivatives may be sugars in which those elements are bonded to multiple bonds, and these derivatives,
  • those having a hydrolyzable protecting group such as an acyl group can be used.
  • unsaturated sugars that may be unsaturated sugars include non-reducing terminal sugars, usually those in which the 4th and 5th carbon positions of glucuronic acid are unsaturated.
  • the low molecular weight hyaluronic acid used in the present invention include those extracted from natural products such as animals, those obtained by culturing microorganisms, and chemically or enzymatically synthesized. Any of these can be used. For example, it can be obtained by a known tissue extraction method and purification method, such as a living tissue force such as a chicken crown, trousers, skin, and joint fluid. It can also be produced by a fermentation method using bacteria belonging to the genus Streptococcus.
  • low molecular weight hyaluronic acid such as a disaccharide consisting of one disaccharide unit and a derivative thereof can be used.
  • low molecular weight hyaluronic acid of about 2 to 20 sugars can be mentioned, more preferably low molecular weight hyaluronic acid of 2 to 6 sugars (molecular weight of about 400 to about 1200), most preferably hyaluronic acid tetrasaccharide. It is.
  • low molecular weight hyaluronic acid is produced by known methods such as an enzymatic decomposition method, an alkaline decomposition method, a heat treatment method, and an ultrasonic treatment method (Biochem., 33 (1994) p6503-6507).
  • the acid is preferably produced by a method of reducing the molecular weight, a method of chemically or enzymatically synthesizing (Glycoconjugate J., (1993) p435-439, WO93 / 20827), and the like.
  • enzymatic degradation methods include hyaluronic acid-degrading enzymes (hyaluronidase (derived from testicles), hyaluronidase (derived from Treptomyces), hyaluronidase SD, etc.), chondroitinase AC, chondroitinase ACII, chondroitinase ACIII, chondroitinase ABC, etc.
  • Hyaluronic acid used in the present invention includes a pharmacologically acceptable salt form, and a pharmaceutically acceptable salt thereof can be used as necessary in the preparation.
  • alkali metal salts such as sodium salt and potassium salt
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • tri (n A) amine salts such as amine salts, triethylenoamine salts, pyridine salts and amino acid salts.
  • the agent of the present invention can be used without any particular limitation, such as hyaluronic acid having a specific molecular weight alone or a mixture of hyaluronic acids having different molecular weights.
  • the therapeutic agent for atopic dermatitis of the present invention comprises hyaluronic acid as an active ingredient, and by administering an effective amount thereof to mammals including humans, symptoms of atopic dermatitis without adversely affecting the living body. Can be improved or prevented.
  • the drug of the present invention can be applied to the affected area and the surrounding skin with low molecular weight hyaluronic acid or a salt thereof as it is or together with a carrier, excipient, or other additives as necessary.
  • it can be formulated into an arbitrary dosage form and administered intra-tissue (injection), orally or menstrually.
  • Examples of the dosage form of the drug to be applied to the skin include ointments, lotions, and creams.
  • the base for these external preparations for skin is not particularly limited as long as it is a base that can be melted, blended or dispersed uniformly in an external preparation.
  • Examples thereof include, but are not limited to, acid, lecithin, purified water and the like.
  • the agent of the present invention may be added with an antioxidant, an antiseptic, a wetting agent, a thickening agent, a buffering agent, an adsorbent, a solvent, an emulsifier, a stabilizer, a surfactant, and the like, if necessary.
  • Agent can be added with an antioxidant, an antiseptic, a wetting agent, a thickening agent, a buffering agent, an adsorbent, a solvent, an emulsifier, a stabilizer, a surfactant, and the like, if necessary.
  • Agent can be added with an antioxidant, an antiseptic, a wetting agent, a thickening agent, a buffering agent, an adsorbent, a solvent, an emulsifier, a stabilizer, a surfactant, and the like, if necessary.
  • Agent can be added
  • an appropriate amount of an ointment containing about 0.05 to 5% of low molecular weight hyaluronic acid can be applied to the affected area and its surroundings several times a day.
  • hyaluronic acid tetrasaccharide can be applied to the affected area at a concentration of 1%.
  • the drug of the present invention can be used as a therapeutic agent for suppressing the progression of symptoms of atopic dermatitis or alleviating the symptoms by applying to the affected area. Applied to the skin or who has a predisposition for atopy but has not developed symptoms, or a patient with atopic dermatitis It can be applied to people who are highly likely to develop atopic dermatitis, such as those in their families, and can be used as a preventive agent to prevent recurrence of atopic dermatitis.
  • Inflammation of the left auricle was produced by sensitization and induction with PiCl in NC mice, and the effect of the HA 4 formulation was examined. As a result, it was observed that inflammation scores such as skin dryness, crust formation, bleeding, hair loss, wrinkling behavior, and auricular thickness associated with inflammation decreased.
  • the test substance, HA4 is specifically prepared by the method of Tawada et al. (Tawada A, Masa T, Oonuki ⁇ , Watanabe A, Matsuzaki Y, Asan A. Large-scale preparation, purirication, and characterization of hyaluronan oligosaccharides from 4- mers to 52-mers. Glycobiolog y. 2002; 12 (7): 421-6 ⁇ ).
  • As the test substance IV-4 formulation a formulation formulated as shown in Table 1 was used.
  • a base-only coating agent not containing ⁇ 4 was used as a control substance. Of the ingredients contained in this drug, except for ⁇ 4, it is a general base material and is known to be effective for skin diseases such as atopic dermatitis.
  • HA4 formulation manufactured by Glucose Research Institute, Inc .: LotNo.060607, HA formulation amount lmg / ml 1 hour before the third induction
  • 0.02 mL was applied to the left auricle using a disposable Brucellin syringe.
  • the HA4 formulation was administered for 5 weeks after the 3rd induction.
  • the remaining 1 group was administered with the control substances listed in Table 1 (manufactured by Glucose Science Laboratory: Lot No. 060607) as a negative control (Table 2).
  • the general condition of each mouse was observed at least once a day, and the body weight was measured at least once a week on the sensitization date, the test end date, and other days. Furthermore, the Student t t test was performed on the body weight and the scores of the following evaluation items.
  • the thickness of the left auricle of the mouse was measured using a mic mouth meter (manufactured by Mitutoyo). For reference, I also measured the right auricle! /.
  • Evaluation score asymptomatic (score 0), mild (score 1), moderate (score 2), severe (score 3)
  • the control group On the day following the administration of HA4 over 5 weeks (36th day of administration), the control group had 1.48 times the same and the test substance group had 1.39 times, and the thickness of the left auricle of the test substance group was higher than that of the control group. Significantly decreased.
  • the left auricle thickness in the test substance group showed a lower value compared to the control group at each measurement point on days 9, 16, 23, and 30 after the start of administration, and there was no significant difference. .
  • the thickness of the right auricle measured as a reference was 5% lower than that of the control group on the day after the 35th day of administration, and the test substance group showed a low value.
  • test substance group 4/5 cases at the 2nd induction, all cases at the 3rd induction, 1/5 cases on the 9th day of administration, mild dryness was observed.
  • Fig. 2 shows photographs of the left pinna of typical individuals in the control group and the test substance group on the 30th day after administration.
  • test substance group shows a lower value than the control group in each item of redness, edema, hair loss, dryness, and crust formation. It showed a low value. In all cases, there were no ulcers or tissue defects in the inflamed areas.
  • Figure 3 shows a graph summarizing the observation results of drought behavior for the control group and the test substance group. In both groups, the number of sputum at the first induction was high at the second induction, and only the test substance group was higher at the third induction.
  • the thickness of the right auricle which is the opposite side to which the test substance was applied, was significantly increased compared to the control group. This suggests that the entire body was moved to the other side. This strongly suggests a successful treatment for atopic dermatitis with systemic symptoms.
  • Example 2 Confirmation of therapeutic effect of HA4 in patients with atopic dermatitis
  • the agent of the present invention the HA4 combination coating agent shown in Table 1 was used.
  • a 16-year-old female (height: 169cm, weight: 50kg) suffering from atopic dermatitis was volunteered and the cream was applied.
  • the patient was diagnosed with atopic dermatitis at an early age and was not completely cured.
  • the patient presents with mild, chronic lesions such as infiltrative erythema, prurigo, crust, rupture, papules, and wrinkles.
  • the patient was applied the above cream on the inside of the elbow for a week after bathing in the morning and evening.
  • hyaluronic acid tetrasaccharide it is a general base material and is not known to be effective in treating atopic dermatitis. Therefore, this effect is considered to be the action of hyaluronic acid tetrasaccharide, suggesting that hyaluronic acid tetrasaccharide is effective in the treatment of atopic dermatitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention a pour objet une composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique. L'invention concerne un agent thérapeutique ou prophylactique pour la dermatite atopique, lequel comprend un acide hyaluronique de faible poids moléculaire en tant qu'ingrédient actif. L'acide hyaluronique de faible poids moléculaire peut être un disaccharide à hexasaccharide de l'acide hyaluronique et on utilise de préférence un tétrasaccharide de l'acide hyaluronique.
PCT/JP2007/070144 2006-10-17 2007-10-16 Agent thérapeutique ou prophylactique pour la dermatite atopique WO2008047779A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008539816A JP5457675B2 (ja) 2006-10-17 2007-10-16 アトピー性皮膚炎の治療薬又は予防薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-282787 2006-10-17
JP2006282787 2006-10-17

Publications (1)

Publication Number Publication Date
WO2008047779A1 true WO2008047779A1 (fr) 2008-04-24

Family

ID=39314007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/070144 WO2008047779A1 (fr) 2006-10-17 2007-10-16 Agent thérapeutique ou prophylactique pour la dermatite atopique

Country Status (2)

Country Link
JP (1) JP5457675B2 (fr)
WO (1) WO2008047779A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010116388A (ja) * 2009-03-10 2010-05-27 Nr Laboratory:Kk 消化管溶性剤型
WO2011109469A1 (fr) * 2010-03-03 2011-09-09 Neocutis Sa Compositions et procédés de traitement de dermopathies et d'affections cutanées au moyen de composés séquestrants à peptide antimicrobien
JP2014227350A (ja) * 2013-05-20 2014-12-08 株式会社テクノーブル 化粧料
JP2015013852A (ja) * 2013-06-04 2015-01-22 キッコーマンバイオケミファ株式会社 肌質改善組成物、食品および医薬品
JP2017514922A (ja) * 2014-05-07 2017-06-08 イルドン・ファーマスーティカル カンパニー リミテッドＩｌｄｏｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ． Ｌｔｄ． 高分子多糖バインダーにコンジュゲートされたラクトバシラスラムノサスｒｈｔ−３２０１、及びこれのアトピー予防及び治療用途
EP2981283A4 (fr) * 2013-04-03 2017-07-05 Cedars-Sinai Medical Center Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
EP3479830A4 (fr) * 2016-04-25 2019-08-21 College of Animal Science & Technology, Qingdao Agriculture University Utilisation d'un fragment d'acide hyaluronique à petites molécules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128159A (ja) * 1989-12-05 1994-05-10 Takeda Chem Ind Ltd 外用剤
JPH07138125A (ja) * 1993-11-19 1995-05-30 Shiseido Co Ltd 皮膚外用剤
JP2004307489A (ja) * 2003-03-25 2004-11-04 Sekisui Chem Co Ltd 皮膚止痒外用組成物
JP2006327958A (ja) * 2005-05-24 2006-12-07 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
JP4065047B2 (ja) * 1998-03-03 2008-03-19 日東光学株式会社 カメラ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5975033A (ja) * 1982-10-21 1984-04-27 オリンパス光学工業株式会社 内視鏡システム
JPS63150209A (ja) * 1986-12-15 1988-06-22 Kanebo Ltd 皮膚化粧料
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
CA2414211C (fr) * 2000-07-07 2011-08-02 Seikagaku Corporation Fractions oligosaccharidiques d'acide hyaluronique et medicament les contenant
JP2006160758A (ja) * 2001-09-25 2006-06-22 Sekisui Chem Co Ltd 皮膚バリア機能改善組成物
JP2004043645A (ja) * 2002-07-11 2004-02-12 Seikagaku Kogyo Co Ltd 低分子化糖の製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128159A (ja) * 1989-12-05 1994-05-10 Takeda Chem Ind Ltd 外用剤
JPH07138125A (ja) * 1993-11-19 1995-05-30 Shiseido Co Ltd 皮膚外用剤
JP4065047B2 (ja) * 1998-03-03 2008-03-19 日東光学株式会社 カメラ
JP2004307489A (ja) * 2003-03-25 2004-11-04 Sekisui Chem Co Ltd 皮膚止痒外用組成物
JP2006327958A (ja) * 2005-05-24 2006-12-07 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKIRA TAWADA ET AL.: "Large-scale preparation, purification, and characterization of hyaluronan oligosaccharides from 4-mers to 52-mers", GLYCOBIOLOGY, vol. 12, no. 7, July 2002 (2002-07-01), pages 421 - 426, XP003022213 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010116388A (ja) * 2009-03-10 2010-05-27 Nr Laboratory:Kk 消化管溶性剤型
WO2011109469A1 (fr) * 2010-03-03 2011-09-09 Neocutis Sa Compositions et procédés de traitement de dermopathies et d'affections cutanées au moyen de composés séquestrants à peptide antimicrobien
US9629856B2 (en) 2010-03-03 2017-04-25 Anteis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
EP2981283A4 (fr) * 2013-04-03 2017-07-05 Cedars-Sinai Medical Center Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
US9763969B2 (en) 2013-04-03 2017-09-19 Cedars-Sinai Medical Center Treatment of inflammatory conditions with hyaluronan disaccharide
JP2014227350A (ja) * 2013-05-20 2014-12-08 株式会社テクノーブル 化粧料
JP2015013852A (ja) * 2013-06-04 2015-01-22 キッコーマンバイオケミファ株式会社 肌質改善組成物、食品および医薬品
JP2017514922A (ja) * 2014-05-07 2017-06-08 イルドン・ファーマスーティカル カンパニー リミテッドＩｌｄｏｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ． Ｌｔｄ． 高分子多糖バインダーにコンジュゲートされたラクトバシラスラムノサスｒｈｔ−３２０１、及びこれのアトピー予防及び治療用途
EP3479830A4 (fr) * 2016-04-25 2019-08-21 College of Animal Science & Technology, Qingdao Agriculture University Utilisation d'un fragment d'acide hyaluronique à petites molécules

Also Published As

Publication number Publication date
JP5457675B2 (ja) 2014-04-02
JPWO2008047779A1 (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
Devaraj et al. Health-promoting effects of konjac glucomannan and its practical applications: A critical review
JP6944399B2 (ja) プロバイオティクス細菌
KR101337578B1 (ko) 의료 장치 및 의약 제형에 유용한 점막 접착성 자일로글루칸 함유 제형
US11524039B2 (en) Topical compositions comprising extract of Coriolus versicolor for autoimmunity enhancement
JPH04500798A (ja) 硫酸化糖類の用途
CN112315882A (zh) 一种舒缓修护保湿面霜及其制备方法
JP5457675B2 (ja) アトピー性皮膚炎の治療薬又は予防薬
JP6429131B2 (ja) 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用
JP2020516684A (ja) 炎症及び炎症性疾患の治療法
JPH08208488A (ja) 皮膚外用剤
WO2008140200A1 (fr) Compositions externes pour la peau
JP2022504792A (ja) 炎症性疾患及び関連する感染の治療方法
KR102353716B1 (ko) 수화 및 윤활 활성을 갖는 약학 조성물
CN108210689A (zh) 一种含有透明质酸的口腔溃疡膜剂及其制备方法
JP2010506908A (ja) グルコサミンまたはグルコサミン誘導体を含むアトピー性皮膚炎治療用組成物およびこれらを使用しアトピー性皮膚炎を治療する方法
US6495531B2 (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
CN114404445B (zh) 环糊精在制备治疗溃疡性结肠炎药物中的应用
TW201124142A (en) Hypersulfated disaccharide formulations
WO2017069793A1 (fr) Compositions de gel vaginal et leurs procédés d'utilisation
CN115721706A (zh) 一种用于治疗湿疹皮炎的组合物及其制备方法与应用
WO2019151285A1 (fr) Composition pour la peau à usage externe
WO2021218964A1 (fr) Extrait de coriolus versicolor pour le traitement de troubles vaginaux ou cervicaux provoqués par des agents infectieux
JP5061143B2 (ja) 皮膚外用剤
JP4786911B2 (ja) アレルギー性疾患処置剤
JPH08301773A (ja) 皮膚掻痒症改善剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07829878

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008539816

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07829878

Country of ref document: EP

Kind code of ref document: A1